Yakup Ergün: Is completion axillary lymph node dissection necessary for adjuvant CDK4/6 inhibitors?

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:

“SENOMAC post-hoc analysis:

Is completion axillary lymph node dissection necessary for adjuvant CDK4/6 inhibitors?

To avoid one DFS event in 5 years with adjuvant abemaciclib, 104 patients will need to undergo cALND.

• 9 of these patients will develop severe impairment in physical arm function.
• 13 patients will exhibit clinical lymphedema symptoms.”

Dario Trapani, Medical oncologist at IEO European Institute of Oncology, shared and commented on Yakup Ergün’s post on X, adding:

“This is a good way to display the tradeoff benefit/harm in pushin’ evidence toward systemic treatments when surgical trials historically showed no added benefits in escalating axillary surgery in breast cancer.

In modern times: no need to escalate axillary surgery inappropriately – applies.”

Source: Yakup Ergün/X and Dario Trapani/X

Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.

Authors: Jana de Boniface, Matilda Appelgren, Robert Szulkin, Sara Alkner,  Yvette Andersson, Leif Bergkvist, Jan Frisell, Oreste Davide Gentilini, Michalis Kontos, Thorsten Kühn, Dan Lundstedt, Birgitte Vrou Offersen, Roger Olofsson Bagge, Toralf Reimer, Malin Sund, Peer Christiansen, Lisa Rydén, and Tove Filtenborg Tvedskov.